Novel Use of Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) on Application of PROSE Devices for Management of Patients with Ocular Surface Disease: A Pilot Study

Novel Use of Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) on Application of PROSE Devices for Management of Patients with Ocular Surface Disease: A Pilot Study2021-06-08T08:25:15-04:00

Novel use of Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) on Application of PROSE Devices for Management of Patients with Ocular Surface Disease: A Pilot Study

Location of Study: BostonSight, Needham

Study Status: Recruiting

The purpose of this placebo/control study is to evaluate Restasis (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD).

ClinicalTrials.gov site here.

[Formstack id=”4409841″ viewkey=”Zu4WKNgoJl” no_style_strict=”true”]